tetano
Editor, Senior Moderator
Vaccine
. 2021 Sep 8;S0264-410X(21)00982-8.
doi: 10.1016/j.vaccine.2021.07.077. Online ahead of print.
Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019
Mark G Thompson[SUP] 1 [/SUP], Giselle Soto[SUP] 2 [/SUP], Alon Perez[SUP] 3 [/SUP], Gabriella Newes-Adeyim[SUP] 4 [/SUP], Young M Yoo[SUP] 5 [/SUP], Avital Hirsch[SUP] 3 [/SUP], Mark Katz[SUP] 3 [/SUP], Yeny Tinoco[SUP] 2 [/SUP], Yonat Shemer Avni[SUP] 6 [/SUP], Eduardo Ticona[SUP] 7 [/SUP], Ryan Malosh[SUP] 8 [/SUP], Emily Martin[SUP] 8 [/SUP], Eduardo Matos[SUP] 9 [/SUP], Sue Reynolds[SUP] 10 [/SUP], Meredith Wesley[SUP] 4 [/SUP], Jill Ferdinands[SUP] 10 [/SUP], Angela Cheung[SUP] 4 [/SUP], Min Levine[SUP] 10 [/SUP], Eduar Bravo[SUP] 11 [/SUP], Carmen Sofia Arriola[SUP] 10 [/SUP], Maria Ester Castillo[SUP] 12 [/SUP], Juan Carlos Castro[SUP] 13 [/SUP], Fatimah Dawood[SUP] 10 [/SUP], David Goldberg[SUP] 3 [/SUP], Joan Manuel Neyra Quijandría[SUP] 2 [/SUP], Eduardo Azziz-Baumgartner[SUP] 10 [/SUP], Arnold Monto[SUP] 8 [/SUP], Ran Balicer[SUP] 3 [/SUP]
Affiliations
Abstract
Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP).
Methods: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016-2017 to 2018-2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018-2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 × 1-hazard ratio (adjusted for sex, age, occupation, and hospital).
Results: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] = -30%, 25%) in Israel and 12% (95% CI = -61%, 52%) in Peru.
Conclusion: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru.
Keywords: Healthcare; Influenza; Vaccine effectiveness.
. 2021 Sep 8;S0264-410X(21)00982-8.
doi: 10.1016/j.vaccine.2021.07.077. Online ahead of print.
Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019
Mark G Thompson[SUP] 1 [/SUP], Giselle Soto[SUP] 2 [/SUP], Alon Perez[SUP] 3 [/SUP], Gabriella Newes-Adeyim[SUP] 4 [/SUP], Young M Yoo[SUP] 5 [/SUP], Avital Hirsch[SUP] 3 [/SUP], Mark Katz[SUP] 3 [/SUP], Yeny Tinoco[SUP] 2 [/SUP], Yonat Shemer Avni[SUP] 6 [/SUP], Eduardo Ticona[SUP] 7 [/SUP], Ryan Malosh[SUP] 8 [/SUP], Emily Martin[SUP] 8 [/SUP], Eduardo Matos[SUP] 9 [/SUP], Sue Reynolds[SUP] 10 [/SUP], Meredith Wesley[SUP] 4 [/SUP], Jill Ferdinands[SUP] 10 [/SUP], Angela Cheung[SUP] 4 [/SUP], Min Levine[SUP] 10 [/SUP], Eduar Bravo[SUP] 11 [/SUP], Carmen Sofia Arriola[SUP] 10 [/SUP], Maria Ester Castillo[SUP] 12 [/SUP], Juan Carlos Castro[SUP] 13 [/SUP], Fatimah Dawood[SUP] 10 [/SUP], David Goldberg[SUP] 3 [/SUP], Joan Manuel Neyra Quijandría[SUP] 2 [/SUP], Eduardo Azziz-Baumgartner[SUP] 10 [/SUP], Arnold Monto[SUP] 8 [/SUP], Ran Balicer[SUP] 3 [/SUP]
Affiliations
- PMID: 34509322
- DOI: 10.1016/j.vaccine.2021.07.077
Abstract
Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP).
Methods: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016-2017 to 2018-2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018-2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 × 1-hazard ratio (adjusted for sex, age, occupation, and hospital).
Results: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] = -30%, 25%) in Israel and 12% (95% CI = -61%, 52%) in Peru.
Conclusion: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru.
Keywords: Healthcare; Influenza; Vaccine effectiveness.